入院降钙素原检测识别不同脓毒症谱系菌血症的可靠性:美国65家医院2008-2017年真实世界使用与性能特征
该回顾性队列研究基于Cerner HealthFacts数据库(2008-2017),纳入65家报告降钙素原医院中入院24小时内同时留取血培养和降钙素原的成人住院患者。739130例留取入院血培养的患者中74958例(10.1%)同时检测了入院降钙素原,其中83%未复查。以≥0.5 ng/mL为界值,降钙素原对菌血症总体敏感性68.2%,不同病原体间从无脓毒症肠球菌菌血症58.0%到肺炎球菌脓毒症96.4%不等;总体区分度仅中等(AUC 0.73;95%CI 0.72-0.73),关键亚组无额外价值。降钙素原阳性与阴性患者的经验性抗生素使用比例无差异(39.7% vs 38.4%)。
要点
- 在65家美国医院中,739130例入院留取血培养的成人患者仅74958例(10.1%)同时检测了入院降钙素原,83%未复查。
- 以≥0.5 ng/mL为界值,入院降钙素原对菌血症总体敏感性68.2%,无脓毒症肠球菌菌血症最低58.0%,肺炎球菌脓毒症最高96.4%。
- 入院降钙素原对总体菌血症的区分度仅中等(AUC 0.73;95%CI 0.72-0.73),在发热/低体温、ICU入住和CDC成人脓毒症事件等关键亚组无额外价值。
- 血培养留取患者中,入院降钙素原阳性者经验性抗生素使用比例39.7%,阴性者38.4%,两者无差异。
- 作者认为,入院降钙素原检测的诊断管理及基于入院降钙素原指导临床决策的风险评估是必要的。
适用人群与场景
- 成人住院患者(≥18岁),在入院24小时内同时留取血培养和降钙素原检测。
- 数据来源为Cerner HealthFacts数据库(2008-2017年),覆盖65家报告降钙素原的医院。
诊断标准与关键阈值
- 脓毒症定义采用美国疾病控制与预防中心(CDC)成人脓毒症事件标准。
- 降钙素原检测界值:≥0.5 ng/mL用于计算对菌血症的敏感性。
研究设计与关键结果
- 研究类型:回顾性队列研究;数据来源:Cerner HealthFacts数据库(2008-2017年);65家报告降钙素原的医院。
- 在739130例入院留取血培养的患者中,74958例(10.1%)同时进行了入院降钙素原检测;接受入院当日降钙素原检测的患者中83%未复查降钙素原。
- 降钙素原中位数因病原体、菌血症来源和急性疾病严重程度而差异显著。
- 以≥0.5 ng/mL为界值,降钙素原对菌血症检测的总体敏感性为68.2%,范围从无脓毒症肠球菌菌血症的58.0%到肺炎球菌脓毒症的96.4%。
- 入院降钙素原对总体菌血症的区分度至多为中等(AUC 0.73;95%CI 0.72-0.73),在关键亚组中未显示额外价值。
- 在留取血培养的患者中,入院降钙素原阳性者经验性抗生素使用比例为39.7%,阴性者为38.4%,两者无差异。
证据类型、等级与局限
- 证据类型:回顾性队列研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,入院降钙素原检测的诊断管理及基于入院降钙素原指导临床决策的风险评估是必要的。
- 入院降钙素原对菌血症的敏感性差(≥0.5 ng/mL时总体68.2%),不能用于排除菌血症。
- 入院降钙素原对菌血症脓毒症和隐匿性菌血症的区分度中等至差(AUC 0.73;95%CI 0.72-0.73),在发热/低体温、ICU入住和CDC成人脓毒症事件等关键亚组无额外价值。
- 入院降钙素原检测未明显改变经验性抗生素使用(阳性者39.7% vs 阴性者38.4%,无差异)。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVES: Serum procalcitonin is often ordered at admission for patients with suspected sepsis and bloodstream infections (BSIs), although its performance characteristics in this setting remain contested. This study aimed to evaluate use patterns and performance characteristics of procalcitonin-on-admission in patients with suspected BSI, with or without sepsis.
DESIGN: Retrospective cohort study.
SETTING: Cerner HealthFacts Database (2008-2017).
PATIENTS: Adult inpatients (≥ 18 yr) who had blood cultures and procalcitonin drawn within 24 hours of admission.
INTERVENTIONS: None.
MEASUREMENTS AND MAIN RESULTS: Testing frequency of procalcitonin was determined. Sensitivity of procalcitonin-on-admission for detecting BSI due to different pathogens was calculated. Area under the receiver operating characteristic curve (AUC) was calculated to assess discrimination by procalcitonin-on-admission for BSI in patients with and without fever/hypothermia, ICU admission and sepsis defined by Centers for Disease Control and Prevention Adult Sepsis Event criteria. AUCs were compared using Wald test and p values were adjusted for multiple comparisons. At 65 procalcitonin-reporting hospitals, 74,958 of 739,130 patients (10.1%) who had admission blood cultures also had admission procalcitonin testing. Most patients (83%) who had admission day procalcitonin testing did not have a repeat procalcitonin test. Median procalcitonin varied considerably by pathogen, BSI source, and acute illness severity. At a greater than or equal to 0.5 ng/mL cutoff, sensitivity for BSI detection was 68.2% overall, ranging between 58.0% for enterococcal BSI without sepsis and 96.4% for pneumococcal sepsis. Procalcitonin-on-admission displayed moderate discrimination at best for overall BSI (AUC, 0.73; 95% CI, 0.72-0.73) and showed no additional utility in key subgroups. Empiric antibiotic use proportions were not different between blood culture sampled patients with a positive procalcitonin (39.7%) and negative procalcitonin (38.4%) at admission.
CONCLUSIONS: At 65 study hospitals, procalcitonin-on-admission demonstrated poor sensitivity in ruling out BSI, moderate-to-poor discrimination for both bacteremic sepsis and occult BSI and did not appear to meaningfully alter empiric antibiotic usage. Diagnostic stewardship of procalcitonin-on-admission and risk assessment of admission procalcitonin-guided clinical decisions is warranted.
参考来源
- Lawandi A, Oshiro M, Warner S, et al. Reliability of Admission Procalcitonin Testing for Capturing Bacteremia Across the Sepsis Spectrum: Real-World Utilization and Performance Characteristics, 65 U.S. Hospitals, 2008-2017. Crit Care Med. 2023. PMID: 37395622. doi:10.1097/CCM.0000000000005968
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。